Abstract 170P
Background
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare primary hepatic malignancy considered to be a variant of hepatocellular carcinoma. It accounts for about ≈ 1-5% of all HCCs .Surgery (resection/liver transplantation) is the current standard treatment and remains the only potentially curative treatment option ; however, the role of chemotherapy is still controversial . Therefore, we conducted this study to evaluate the efficacy of chemotherapy in improving the survival of patients with Fibrolamellar hepatocellular carcinoma (FL-HCC).
Methods
Using SEER database, we extracted the data of 100 patients with FL-HCC from 2004 to 2014. There were 40 (40%) patients underwent surgery combined with chemotherapy, while 60(60%) of them received chemotherapy only. Patients’ demographics and staging system were assessed.
Results
Patients with FL-HCC had better outcomes when they received surgery alone compared to those who received surgery combined with chemotherapy, where overall 1-year relative survival rates were 98.3% and 95%, respectively (significant p value of 0.031).Subgroup analysis revealed that there is a highly significant P-value (< 0.0001) regarding both different age groups and staging system. On the other hand ;there is No significance for the p value was reported to the race or sex.Table:
170P
Variables | Survival of Patients | p value | |
---|---|---|---|
surgery combined with chemotherapy | Surgery alone | ||
Sex Male Female | 92.3% 100% | 100% 95.7% | 0.246 |
Age 0-19 20-39 40-59 60-79 | 100% 84.6% 100% 100%** | 100% 100% 100% 81.8% | <0.0001*** |
Race White Black Asian or Pacific Islander | 96.7% 100%** 85.7% | 98% 100% * | 0.838 |
staging I II IIIA IIIB IIIC IV | 100% 100%** 100% 100%** 100% 85.7% | 96.4% 100% 100% 100%** 100% 100% | <0.0001*** |
Highly significant P-value < 0.0001.
**few patients reported.
*NO recorded patients.
Conclusions
surgery alone without chemotherapy in patients with FL-HCC shows higher 1-year relative survival rates when compared to surgery combined with chemotherapy. So, we recommend surgery alone without chemotherapy as a superior modality for better survival. Further studies should be conducted on a larger number of patients to confirm the results. Keywords: Fibrolamellar hepatocellular carcinoma (FL-HCC), chemotherapy, surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yasmine Ashraf Mohamed Ali.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract